Opko Health Receives Buy Rating from Jefferies Group (OPK)
Opko Health (NYSE:OPK)‘s stock had its “buy” rating restated by investment analysts at Jefferies Group in a note issued to investors on Wednesday. They currently have a $10.50 price target on the stock, down from their previous price target of $11.00. Jefferies Group’s price objective points to a potential upside of 15.64% from the stock’s previous close.
Separately, analysts at TheStreet upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $12.00.
In other Opko Health news, CEO Phillip Md Et Al Frost bought 5,000 shares of the company’s stock on the open market in a transaction that occurred on Monday, August 4th. The stock was purchased at an average cost of $8.75 per share, with a total value of $43,750.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Opko Health (NYSE:OPK) opened at 9.08 on Wednesday. Opko Health has a one year low of $7.32 and a one year high of $12.95. The stock’s 50-day moving average is $8.88 and its 200-day moving average is $8.78. The company’s market cap is $3.757 billion. Opko Health also was the recipient of unusually large options trading activity on Monday. Investors acquired 2,916 put options on the stock. This is an increase of 286% compared to the average volume of 755 put options.
Opko Health (NYSE:OPK) last released its earnings data on Monday, August 11th. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.09) by $0.03. The company had revenue of $23.50 million for the quarter, compared to the consensus estimate of $23.70 million. During the same quarter in the prior year, the company posted ($0.01) earnings per share. The company’s quarterly revenue was down 1.3% on a year-over-year basis. On average, analysts predict that Opko Health will post $-0.37 earnings per share for the current fiscal year.
OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.